IP Library Granted Patent US 9,173,917
Granted Patent B2
US 9,173,917 · App. 13/547,430 · Granted Nov 3, 2015

Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug

Inventors: Herbert T. Nagasawa (Richfield, MN); Jonathan F. Cohen (Prior Lake, MN)
Assignees: Max International, LLC; The United States of America as represented by the Department of Veteran Affairs
A61K38/063
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,173,917
App. No.
13/547,430
Granted
Nov 3, 2015
Kind
B2
Abstract

The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.

Claims (12)

1. A method for reducing oxidative stress in a cell comprising administering L-CySSG to a subject, wherein L-CySSG is cleaved in the subject and releases cysteine and glutathione in the subject to reduce oxidative stress in the cell.

2. The method of claim 1 , wherein the cell has decreased or depleted cellular levels of glutathione.

3. The method of claim 1 , wherein the oxidative stress is caused by a toxic substance, a pathogen, ultraviolet light, physical injury or genetic disease.

4. The method of claim 3 , wherein the toxic substance is a drug, alcohol, metal ion, ultraviolet light or radiation.

5. The method of claim 4 , wherein the drug is acetaminophen, aminoglycoside antibiotic or a chemotherapeutic drug.

6. The method of claim 3 , wherein the pathogen is HIV or anthrax spores.

7. The method of claim 1 , wherein reducing oxidative stress reduces an injury caused by an infection, cardiovascular disease, genetic disease, physical injury, ophthalmic disease, cancer, inflammation, neuropathy, acute respiratory distress syndrome (ARDS), exposure to a toxic substance, exposure to ultraviolet light, exposure to radiation and/or decreased levels of glutathione.

8. The method of 1 , wherein L-CySSG is administered via aerosol, intravenous, intramuscular, subcutaneous, implantable pump, continuous infusion and/or oral administration.

9. The method of claim 1 , wherein the subject is selected from the group consisting of human, monkey, dog, cat, cow, sheep, horse, rabbit, mouse, and rat.

10. The method of claim 1 , wherein the subject is human.

11. The method of claim 1 , wherein L-CySSG is administered to the subject in an amount of 0.2 to 2.5 mmol/kg body weight of the subject.

12. The method of claim 1 , wherein L-CySSG is administered to the subject in an amount of 50-500 milligrams per day.

Assignments (5)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 5, 2021
From: MAX INTERNATIONAL, LLC
To: EAST WEST BANK
Reel/Frame 058809/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2013
From: COHEN, JONATHAN F.
To: CELLGEVITY, INC.
Reel/Frame 030794/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2013
From: CELLGEVITY, INC.
To: MAX INTERNATIONAL, LLC
Reel/Frame 030795/0218 →
COMMUNICATION REGARDING ASSIGNMENT Recorded Jul 15, 2013
From: DEPARTMENT OF VETERANS AFFAIRS
To: DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 030795/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2013
From: NAGASAWA, HERBERT T.; COHEN, JONATHAN F.
To: DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 030792/0153 →
Continuity (4)
Continuation 12190556 · Aug 12, 2008
Continuation 10750005 · Dec 30, 2003
Provisional Application 60437872 · Jan 3, 2003
Related Publication 20120295855A1 · Nov 22, 2012